Verastem Oncology Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Buildings collapse as quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Verastem (VSTM) Misses Q1 EPS by 5c, Revenues Miss; FY19 Revenue Guidance Below Consensus
May 9, 2019 4:47 PM EDTVerastem (NASDAQ: VSTM) reported Q1 EPS of ($0.52), $0.05 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $1.67 million versus the consensus estimate of $2.91 million.
We are now into the second full quarter of the COPIKTRA launch and sales were up approximately 38% compared to the prior quarter, said Robert Forrester, President and Chief... More
